Download Functional Neoplasm

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
MANAGEMENT OF
ADNEXAL MASSES
Objectives
• Understand which adenexal masses
require surgery verses following
• Understand how to identify potentially
malignant adenexal masses
• Decide which patients with adenexal
masses should be referred to a
gynecologic oncologist
Adnexal masses
• Management is often driven by concern for
malignancy
– 289,000 admissions per year for ovarian
neoplasms
– 22,000 new cases ovarian cancer per year
• Risk of malignancy within an ovarian
neoplasm varies with age
– Peak age is in a women’s 60’s
Adnexal Masses in Reproductive
Age Women
Adnexal masses in reproductive
age women
• Of non-inflammatory ovarian tumors
– 70% functional cysts
– 20% benign tumors
– 10% endometriomas
– ?% tuboovarian complexes/abscesses
Ultrasound evaluation of adnexal
masses
Functional
•
•
•
•
•
Unilateral
Simple cyst
Smooth wall
No ascites
Resolution over 4-6
weeks
• <10 cm
Neoplasm
•
•
•
•
•
•
Bilateral
Complex
Solid components
Internal papillations
Ascites
Persistence or growth
Ultrasound: Benign ovarian cyst
Ultrasound: Ovarian cancer
Presumed functional cysts in
reproductive age women
• Observe for 3 months
• OCPs do not increase likelihood of
resolution, but can decrease risk of
recurrence
Adnexal Masses in
Postmenopausal Women
Adnexal masses in
postmenopausal women
• They are not functional cysts and will not
go away
• Most are benign some are malignant
• Concerns about torsion, growth, and
missing a malignancy usually lead to
removal of adenexal masses
Ovarian cancer symptoms
• Ovarian cancer is called the “silent killer”
(probably not true)
• Generally patient and physician ignore the
symptoms
• One of the best ways to detect early ovarian
cancer is for both the patient and the physician
to maintain a high index of suspicion of the
diagnosis in the symptomatic woman
Ovarian cancer symptoms
• 95% of patients reported having symptoms
prior to diagnosis
– Abdominal 77%
– Gastrointestinal 70%
– Pain 58%
– Constitutional 50%
– Urinary 34%
– Pelvic 26%
Evaluation
• Physical examination
– Including pelvic examination
• Transvaginal ultrasonography
• CT scan of abdomen and pelvis (optional)
• Ca-125
– Should only be done if mass found
– Less useful in the premenopausal woman
Ca-125
• Antigenic determinant located on large, mucinlike glycoprotein found on cells derived from
coelomic epithelium (pericarium, pleura,
peritoneum) and Mullerian epithelium (tubal,
endometrial, endocervical)
• Expressed by 80% nonmucinous epithelial
ovarian cancers
• Up to 50% of early stage ovarian cancers and
20-25% of advanced stage ovarian cancers are
associated with normal Ca-125 values
Ca-125
• Normal range in most labs < 35 U/ml
• Sensitive marker of response to treatment
and disease status in patients with ovarian
cancer
• Can be used in triage of ovarian masses
– Less useful in premenopausal women
because many benign conditions can cause
“false” elevations
• Not useful for screening
Screening Ca-125
• 39,114 menopausal women followed 4
years with Ca-125 and ultrasound
• 90 cases of ovarian cancer
• 60 were found due to the screening
• 80% were stage III or IV
• 1170 surgeries required to find the 60
cases
Conditions which may cause a
“false” elevation of Ca-125
• Benign ovarian cysts
• Uterine leiomyomata
• Pelvic inflammatory
disease
• Endometriosis
• Adenomyosis
• Pregnancy
• Menstruation
•
•
•
•
•
•
•
•
Heart failure
Liver failure
Renal failure
Peritoneal
tuberculosis
Diverticulitis
Pancreatitis
Recent abdominal or
thoracic surgery
Other malignancies
Should the patient have
surgery by general
gynecologist or gyn
oncologist?
Why consult a gynecologic
oncologist?
Accurate staging
• Complete surgical staging:
– 97% gynecologic oncologists
– 52% general obstetrician/gynecologists
– 35% general surgeons
• Better prognosis with complete surgical
staging in early disease
McGowan L, et al. Misstaging of ovarian cancer. Obstet Gynecol 1985;65:568-72.
Optimal cytoreduction results in
improved survival in ovarian cancer
Slide courtesy of Gynecologic Cancer Foundation
Who should be referred to a
gynecologic oncologist?
• Women who have a pelvic mass that is
suspicious for a malignant ovarian
neoplasm, as suggested by at least one of
the following indicators:
– Elevated Ca-125 level
• Premenopausal > 200 units/ml
• Postmenopausal > 35 units/ml
– Ascites
– A nodular or fixed pelvic mass
– Evidence of abdominal or distant metastasis
Ovarian Torsion
Pathogenesis
• Generally associated with ovarian mass
but can occur with normal ovaries
• Generally both the tube and ovary are
envolved but either structure can torse
alone
• Generally with cysts that are >5cm
• Less likely with old PID or malignancies
due to the adhesions
• Generally in reproductive age women
Clinical Presentation
• Acute moderate to severe pelvic pain –
90%
• Adenexal mass – 90%
• Nausea and vomiting – 47 to 70%
• Fever – 2 to 20%
• Abnormal uterine bleeding – 4%
Evaluation
• Abdomenal and pelvic exam
demonstrating tenderness and generally
rebound
• Lab
– Hcg, CBC
• Ultrasound
– Adenexal mass with diminished venous blood
flow intially, no blood flow later
Treatment
• Surgery, the sooner the better
• If done soon enough, you can save the
ovary